- 1 Title: Identifying potential risk genes and pathways for
- 2 neuropsychiatric and substance use disorders using intermediate
- 3 molecular mediator information
- 4
- <sup>5</sup> Huseyin Gedik<sup>a</sup>, Tan Hoang Nguyen<sup>b</sup>, Roseann E. Peterson<sup>c,d</sup>,
- <sup>6</sup> Christos Chatzinakos<sup>e,f</sup>, Brien P. Riley<sup>b</sup>, Vladimir I.

7 Vladimirov<sup>g</sup>, Silviu-Alin Bacanu<sup>b</sup>

- 8
- 9 <sup>a</sup> Integrative Life Sciences, Virginia Institute of Psychiatric and Behavioral Genetics, Virginia
- 10 Commonwealth University, Richmond, VA, USA
- 11 <sup>b</sup> Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia
- 12 Commonwealth University, Richmond, VA, USA
- 13 <sup>c</sup> Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA
- <sup>d</sup> Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University,
- 15 Brooklyn, NY, USA
- 16 <sup>e</sup> Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- <sup>17</sup> <sup>f</sup> Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA
- <sup>g</sup> Department of Psychiatry, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA
- 19 Short Title: Identifying potential causal genes and pathways
- 20 Corresponding Author:
- 21 Full name: Huseyin Gedik
- 22 Department: Integrative Life Sciences
- 23 Virginia Commonwealth University
- 24 800 E Leigh Street
- 25 Richmond, VA, 23219, United States
- 26 Email: gedikh@vcu.edu
- 27
- 28 Keywords: eQTL, pQTL, mQTL, Mendelian randomization, Alcohol Use Disorder, Bipolar
- 29 Disorder, Schizophrenia

30

#### Abstract

31 Neuropsychiatric and substance use disorders (NPSUD) have a complex etiology that includes 32 environmental and polygenic risk factors with significant cross-trait r<sub>G</sub>. Genome Wide Association 33 Studies (GWAS) of NPSUD yield numerous association signals. However, for most of these 34 regions, we do not yet have a firm understanding of either the specific risk variants or the effects 35 of these variants. Post-GWAS methods allow researchers to use GWAS summary statistics and 36 functional genomics data to infer the likely molecular mediators (transcript, protein and 37 methylation abundances) for the effect of variants on disorders. One group of post-GWAS 38 approaches is commonly referred to as transcriptome/proteome/methylome wide association 39 studies, which are abbreviated as T/P/MWAS (or collectively as XWAS). Since these approaches 40 use biological mediators, the multiple testing burden is reduced to the number of genes ( $\sim 20,000$ ) 41 instead of millions GWAS SNPs leading to increased signal detection. In this work, our aim is to 42 uncover likely risk genes for NPSUD by performing XWAS analyses in two tissues - blood and 43 brain. Firstly, XWAS using the Summary-data based Mendelian Randomization (SMR), which 44 takes GWAS summary statistics, reference xQTL data and a reference LD panel as inputs, was 45 conducted to identify putative causal risk genes. Second, given the large comorbidities among 46 NPSUD and the shared cis-xOTLs between blood and brain, we improved XWAS signal detection 47 in NPSUD for underpowered analyses by performing joint concordance analyses between XWAS 48 results i) across the two tissues and ii) across NPSUD. All XWAS signals i) were adjusted for 49 HEIDI (non-causality) p-values and ii) used to test for pathway enrichment. The results suggest 50 that there were widely shared gene/protein signals within the Major Histocompatibility (MHC) 51 region on chromosome 6 (BTN3A2 and C4A) and elsewhere in the genome (RERE, FURIN, 52 ZDHHC5 and NEK4). The identification of putative molecular genes and pathways underlying 53 risk may offer new targets for therapeutic development. Some of our analyses' more immediate 54 actionable signals might relate to vitamins, i.e., i) in KYAT3 (a part of the kynurenine pathway 55 with vitamin  $B_6$  as a cofactor) for post-traumatic stress disorder and ii) omega-3 and vitamin D 56 pathways for bipolar disorder.

- 57
- 58
- 59

#### 60 **1. Introduction**

61

Genome-wide association studies (GWAS) have identified numerous loci associated with 62 neuropsychiatric and substance use disorders (NPSUD), supporting the high polygenicity of 63 64 NPSUD. Furthermore, NPSUD's risk loci have not been fully discovered (Owen and Williams, 65 2021). For instance, the largest GWAS for schizophrenia (SCZ) found 287 independent loci and 66 estimates that the common variants explain only 24% of the phenotypic variance (Trubetskoy et 67 al., 2022). Similarly, other NPSUD GWAS yield large numbers of genome-wide significant 68 signals (Howard et al., 2019; Nievergelt et al., 2019; Sanchez-Roige et al., 2019; Mullins et al., 69 2021) capturing a statistically significant but small proportion of the phenotypic variance. Since 70 most genome-wide significant signals reside in non-protein coding genomic regions (Edwards et 71 al., 2013), the interpretation of these GWAS findings are not straightforward. Performing post-72 GWAS analyses, that infer associations between genes or molecular pathways and traits, could 73 significantly advance our understanding of these GWAS signals.

74

75 Associated variants are thought to influence risk through altered gene regulation, for example, via 76 epigenetic changes, yielding changes in RNA levels or protein abundance. Molecular quantitative 77 loci mapping studies empirically support this assumption. They found that expression quantitative 78 trait loci (eQTL) (Ongen et al., 2017), protein QTL (pQTL) (Robins et al., 2021) and methylation 79 QTL (mQTL) (Hannon et al., 2016) colocalize with disease-associated loci. However, while there 80 are many well-powered GWAS scans in NPSUD (Pardiñas et al., 2018; Demontis et al., 2019; 81 Grove et al., 2019; Howard et al., 2019; Nievergelt et al., 2019; Watson et al., 2019; Johnson et 82 al., 2020; Polimanti et al., 2020; Mullins et al., 2021; Trubetskoy et al., 2022), none of these studies 83 directly assayed the transcriptome, proteome or methylome for their cohorts.

84

However, researchers found ways around this assessment limitation in GWAS cohorts. They formed large reference molecular e/p/mQTL (henceforth denoted as xQTL) datasets readily available for blood and brain (Sun et al., 2018; van der Wijst et al., 2020; Ferkingstad et al., 2021; Võsa et al., 2021; Yang et al., 2021a; Zhang et al., 2021). Researchers have developed methods to integrate these molecular xQTL data and GWAS summary statistics to impute the association between phenotypes and molecular mediators (transcriptome, proteome and methylome). Such analyses are widely referred to as transcriptome-wide association studies (TWAS), proteome-wide

92 association studies (PWAS) and methylome-wide association studies (MWAS) (Gamazon et al., 93 2015; Gusev et al., 2016; Zhu et al., 2016; Barbeira et al., 2018, 2019; Hu et al., 2019; Nagpal et 94 al., 2019; Bae et al., 2021) – henceforth collectively referred to as XWAS. Moreover, since they 95 directly model relevant biological mediators, these approaches could identify putatively causal genes but they fail to eliminate pleiotropy (Wainberg et al., 2019). Until recently, XWAS analyses 96 97 of NPSUD were mostly TWAS (Zhu et al., 2016; Niu et al., 2019; Hammerschlag et al., 2020; 98 Kapoor et al., 2021). However, PWAS is also increasing in number with the expanding pQTL 99 reference data in brain (Wingo et al., 2021, 2022). Besides eQTL and pQTL, mQTL has also been 100 investigated as a risk factor (Perzel Mandell et al., 2021; Shen et al., 2022). Recently, MWAS also 101 yielded significant genes for NPSUD (Sugawara et al., 2018; Aberg et al., 2020; Howard et al., 102 2022).

103

104 Changes in gross anatomical and cell type specific phenotypes have been observed for NPSUD 105 and associated risk alleles via *in vitro* and postmortem studies (Brennand et al., 2012; Schrode et 106 al., 2019; Zhang et al., 2020). Functional genomic profiles differ by cell type (Marstrand and Storey, 2014; Buenrostro et al., 2015) and cell type composition differs across brain regions (Wang 107 108 et al., 2018). In addition, different neuronal cell types have different functional profiles and 109 different distributions across regions (Kelley et al., 2018). Genetic variants contributing to the 110 heritability of certain NPSUD were enriched in cis-regulatory elements that are specific to 111 GABAergic and glutamatergic neurons (Sanchez-Priego et al., 2022). Thus, integrating cell type 112 specific xQTL with GWAS findings is very promising. However, due to expense and other factors, 113 sample sizes for functional profiles in specific cell types across brain regions are still small 114 (Spaethling et al., 2017; Bryois et al., 2022) and limited in detection power. Consequently, most 115 functional genomics data available to support xQTL mapping studies come from bulk brain tissue 116 (Consortium, 2020) rather than single cell (Bryois et al., 2022) or sorted cell types (Aygün et al., 117 2021), and despite their limited cellular resolution, the use of bulk tissue and meta-analysis across 118 tissues are currently still more powerful.

119

To conduct XWAS, two common approaches, TWAS (Gusev et al., 2016) and PrediXcan (Gamazon et al., 2015) have been used, with both requiring pre-computing of SNP weights from xQTL data sets. To avoid LD confounding, these XWAS tools also require a subsequent fine

mapping step – e.g., TWAS-FOCUS (Mancuso et al., 2019). In contrast, Mendelian Randomization (MR) based methods (Zhu et al., 2016; Yuan et al., 2020; Zhou et al., 2020) do not need the pre-computation of SNP weights and test for inference in a two-step regression framework. Among MR based XWAS methods, summary data-based Mendelian Randomization (SMR) is among the most commonly used method (Zhu et al., 2016). It has the advantage of providing users with a heterogeneity in independent test (HEIDI) to filter out non-causal loci that may be just in linkage with causal signals.

130

131 There is widespread comorbidity among NPSUD (Plana-Ripoll et al., 2019). This is in part due to 132 shared genetic risk factors (Lee et al., 2019), e.g., as detected by genetic correlation (r<sub>G</sub>) in cross-133 trait analyses (THE BRAINSTORM CONSORTIUM et al., 2018). Consequently, it is possible 134 that there could be many shared XWAS signals among NPSUD. This supports the joint analysis 135 of NPSUD to potentially increase detection power, especially for underpowered disorders (Turley 136 et al., 2018; Gleason et al., 2020; Taraszka et al., 2022). Additionally, there is significant 137 concordance of cis-eOTL and cis-mOTL effects between blood and brain (Oi et al., 2018) and 138 more than 70% of pQTL are shared between blood and brain (Yang et al., 2021a). Moreover, the 139 direction of effect across most tissues for shared eQTLs is the same (THE GTEX CONSORTIUM 140 et al., 2015). Consequently, given the high comorbidities between traits and xQTL concordance 141 between tissues, a joint analysis of the XWAS results from all traits and tissues would likely help 142 to uncover novel signals, especially for relatively underpowered NPSUD and tissues (e.g., brain). 143

In this study, SMR was used to perform blood and brain XWAS of NPSUD to identify potential molecular mediators among major psychiatric disorders. To increase signal detection in underpowered disorders and tissue (brain), comorbidities among NPSUD and tissue xQTL concordances were leveraged in the joint trait/tissue concordance analysis. Subsequent analyses of XWAS signals were used to identify putative risk loci and pathways, shedding light on the etiology of NPSUD.

150 151

- 152 **2. Materials and Methods**
- 153 2.1 Statistical Method

154 We performed univariate XWAS analyses for nine NPSUD [Attention Deficit and Hyperactivity 155 Disorder (ADHD), Autism Spectrum Disorder (ASD), Alcohol Use Disorder (AUD), Bipolar 156 Disorder (BIP), Cannabis Use Disorder (CUD), Major Depressive Disorder (MDD), Opioid 157 Use/Dependence Disorder (OD), Post-Traumatic Stress Disorder (PTSD) and Schizophrenia 158 (SCZ)] (Table 1) for three paradigms (TWAS, PWAS and MWAS) and two tissues (blood and 159 brain). For this purpose, we used SMR (v.1.03) (Zhu et al., 2016) to infer the association between 160 the transcriptome/proteome/methylome and NPSUD. We performed SMR analysis for GWAS of 161 NPSUD (Table 1) using external xQTL reference data sets (Table 2). To prioritize genes and perform pathway analyses, we adjusted probe (RNA/protein/CpG) SMR p-value (P<sub>SMR</sub>) for HEIDI 162 test p-value ( $P_{HEIDI}$ ), by combining the two p-values into a single one by requiring that i)  $P_{SMR}$  is 163 not penalized when  $P_{HEIDI}$  is above 0.01 and ii)  $P_{SMR}$  was penalized by the amount  $P_{HEIDI}$  falls 164 below 0.01. Consequently, we adjusted  $P_{SMR}$  to  $P'_{SMR} = \frac{P_{SMR}}{\min(\frac{P_{HEIDI}}{0.01}, 1)}$ . We used this approach 165 instead of filtering by  $P_{HEIDI} < 0.01$  because a misalignment between the GWAS cohort 166 167 population and the European LD reference panel used by SMR might yield very low  $P_{HEIDI}$ , e.g., the well-known C4A in our SCZ TWAS ( $P_{HEIDI} = 5.94 \times 10^{-4}$ ) Subsequently, to extend the 168 inference to pathways, we performed a gene set enrichment analysis for suggestive  $(P'_{SMR} <$ 169  $\frac{1}{number of \ probes}$ ) signals (Figure 1). 170

171

### 172 2.2 Parameters for SMR-based XWAS analyses

SMR analyses was performed for only cis-xQTLs (SNPs with p-value  $< 5x10^{-8}$  within 2 Mbp of 173 174 the probe). We also used the default maximum (20) and minimum (3) number of xQTLs selected for the HEIDI test. We set the significance threshold as  $< 1.57 \times 10^{-3}$  for xQTL p-values and the 175 176 mismatch of minimum allele frequency among input files as < 15%. For HEIDI test, SNPs with 177 LD > 0.9 and < 0.05 with top associated xQTL SNP were pruned. In case-control studies, we log-178 transformed the odds ratio as suggested by the SMR analysis guidelines 179 (https://yanglab.westlake.edu.cn/software/smr/#SMR&HEIDIanalysis, accessed on August 3, 180 2022).





**Figure 1.** Flowchart of SMR XWAS analyses paired in both blood and brain tissues. To penalize for heterogeneity (non-causality), we employed an adjusted probe p-value  $[P'_{SMR} = P_{SMR}/\min(P_{HEIDI}/0.01,1)]$ . For gene set enrichment analysis, we used the suggestive signals (expected to occur once per scan by chance). Primo method was used to conduct multi-trait analysis and Functional Mapping and Annotation (FUMA) was used for gene set enrichment analysis.

188

# 189 2.3. Neuropsychiatric and substance use disorders GWAS

- 190 All summary statistics except for AUD (Table 1) were downloaded from the Psychiatric Genomics 191 Consortium (PGC web portal (https://www.med.unc.edu/pgc/download-results/, accessed on 192 December 15 2023). For AUD GWAS summary statistics, we had access to the data granted 193 through NIH the Million Veteran Program (MVP) (dbGaP from Study 194 Accession: phs001672.v6.p1). For SMR analysis, GWAS summary statistics were processed into 195 the SMR-ready file format. The positions for all variants and genes in the input files (LD reference 196 panel, GWAS summary statistics, and xQTL summary statistics files) for the SMR analysis are 197 based on the GRCh37/hg19 reference genome.
- 198
- **Table 1.** Summary statistics of eight major PGC GWAS and MVP AUD GWAS.

200

Neuro Psychiatric and	GWAS significant	Study	Number of cases
substance use	markers*/total		and controls /
disorders	markers		ancestry
Attention deficit and	317 / 8,094,095	(Demontis et al.,	19,099 - 34,194 / EUR
hyperactivity disorder		2019)	
(ADHD)			
Autism spectrum	93 / 7,822,833	(Grove et al., 2019)	18,381 - 27,969 / EUR
disorder (ASD)			
Alcohol use disorder	588 / 6,895,251	(Kranzler et al.,	34,658 -167,346 / EUR
(AUD)		2019)	
Bipolar disorder (BIP)	3,205 / 7,608,184	(Mullins et al.,	41,917 - 371,549** /
		2021)	EUR
Cannabis use disorder	29 / 7,735,104	(Johnson et al.,	17,193 - 357,987 /
(CUD)		2020)	EUR
Major depressive	4,625 / 7,286,335	(Howard et al.,	411,965 - 1,285,068 /
disorder		2019)	EUR
(MDD)			
Opioid use/dependence	0 / 4,571,339	(Polimanti et al.,	4,503 - 32,500 / EUR
disorder		2020)	
(OD)			
Post-traumatic stress	3,434 / 3,875,929	(Nievergelt et al.,	30,000 - 170,000 /
disorder (PTSD)		2019)	EUR
Schizophrenia	22,344 / 7,585,077	(Trubetskoy et al.,	33,640 - 43,456 /
(SCZ)		2022)	mostly EUR

\* Unpruned (based on LD) variants with

\*\* Case group includes bipolar or unipolar and control groups include individuals without any such diagnosis.

EUR: European

201

202 2.4. Molecular xQTL reference data sets

For our analyses, to get the highest signal detection, we selected the largest publicly available blood and brain xQTL datasets (Table 2). When pQTL summary statistics from reference data were not available (blood and brain pQTL) in the SMR-required input binary file format (i.e., .besd), we processed them into this .besd format. Below, we provided some of the most relevant details for these data sets. (A list of URLs for each data set is available in Supplementary Table 1, and for more details, please see the extended summary information in the Supplementary material)

209

# 210 2.4.1 eQTL reference datasets

211 For TWAS, we obtained the blood eQTL data from eQTLGen (Võsa et al., 2021) and brain eQTL 212 from BrainMeta v2 (Oi et al., 2022) (Table 2). eOTLgen consortium meta-analyzed 31,684 213 samples from 37 different study cohorts. Genotyping and gene expression levels were assayed 214 mainly from whole blood (34 out of 37) and part peripheral blood mononuclear cells (3 out of 37). 215 Most cohorts (25 out of 37) were population-based. The following eQTLGen studies included 216 individuals of non-European ancestry (e.g., the Singapore Systems Immunology cohort - n = 115; 217 Morocco -n = 175; Bangladeshi Vitamin E and Selenium Trial -n = 1,404). eOTLgen inferred 218 cis-eQTL effects for 16,987 expression Genes (eGenes). BrainMeta (version 2) is a meta-analysis 219 of brain eQTL mapping studies from seven independent cohorts (Qi et al., 2022). The study 220 consists of 2,443 unrelated individuals of European ancestry. BrainMeta v2 detected 1,962,114 221 eQTL SNPs for16,744 eGenes.

222

## 223 2.4.2 pQTL reference datasets

For PWAS, we used the blood pQTL data from deCODE (Ferkingstad et al., 2021) and brain pQTL from Wingo et al. (Wingo et al., 2022) (Table.2). The deCODE proteome study consisted of 35,559 individuals from Iceland. Blood plasma samples were assayed for 4,907 probes [Slow Offrate Modified Aptamer Scan (SOMAScan) (Gold et al., 2010, 2012) assay version 4 aptamers], which correspond to 4,719 unique proteins.

229

The brain pQTL study sampled three regions of the brain: prefrontal cortex, dorsolateral prefrontal
cortex and parahippocampal gyrus (Wingo et al., 2022) in 722 samples. It used isobaric tandem

mass tag method to assay proteins and 9,363 of them met the quality control criteria. While the

sample size of brain pQTL reference data is relatively small, this was the largest publicly availablesuch study at the time of completion for the analyses.

235

## 236 2.4.3 mQTL reference datasets

For MWAS analyses, we used the blood (McRae et al., 2018; Wu et al., 2018) and brain mQTL

- data sets (Qi et al., 2018) (Table.2), which are publicly available for download from SMR web
- 239 portal (https://yanglab.westlake.edu.cn/software/smr/#DataResource, accessed on January 28
- 240 2023). The mQTL data for the brain is a meta-analysis of the mQTL mapping results from three
- 241 major studies (Hannon et al., 2016; Jaffe et al., 2016; Ng et al., 2017). The methylation assay used
- in these studies was the Illumina Infinium Human Methylation 450K array. We used the annotation
- file provided by the manufacturer to map the CpG probe ids (with "cg" prefix) to the HUGO gene
- 244 nomenclature committee (HGNC) gene symbol.
- 245

# 246 **Table 2.** Reference xQTL molecular datasets used for XWAS studies.

Study	Tissue	Sample	Publication	Genotype	Probe assay	Number of
		size				probes in
						SMR
						analysis
reference e(	)TL data					
eQTLGen	peripheral	31,684	(Võsa et al.,	SNP	Expression	19,250
	blood		2021)	array	Array and	
					RNA-seq	
BrainMeta	Brain cortex	2,865	(Qi et al.,	SNP	Expression	16,744
v2*		(effective	2022)	array/	Array and	
		sample		WGS	RNA-seq	
		size: 2,443)				
reference pQTL data						
deCODE**	Blood	35,559	(Ferkingstad	SNP	SOMAscan	4,773
	plasma		et al., 2021)	array/		

				WGS		
ROS/MAP-	dPFC+	366+70/15	(Wingo et	WGS	TMT	9,346
Banner-	FC/	1/ 135	al., 2022)		isobaric	
MSBB	dPFC/				labeling MS	
	PG					
reference m	QTL data					
Blood	Peripheral	1,980	(McRae et	SNP	Illumina	94,338
mQTL***	blood		al., 2018;	array	Human	
			Wu et al.,		Methylation	
			2018)		450 array	
Brain	dPFC/	1,160	(Qi et al.,	SNP	Illumina	436,077
mQTL****	Fetal brain		2018)	array	Human	
					Methylation	
					450 array	
					150 ulluy	

**SOMAScan**: Slow Off-Rate Modified Aptamer scan, **WGS**: Whole genome sequencing, **ROS**: Religious Orders Study, **MAP**: Rush Memory and Aging Project, **MSBB**: Mount Sinai NIH Neurobiobank, **dPFC**: dorsolateral prefrontal cortex, **FC**: Frontal Cortex, **PG**: parahippocampal gyrus, **TMT**: Tandem Mass Tag, **MS**: Mass Spectrometry

\* This data is a meta-analysis of the GTEx brain, CMC, and ROS/MAP by using MeCS (Qi et al., 2018).

\*\* One group of participants is from deCODE and the second group is from the Icelandic Cancer Project.

\*\*\* Meta-analysis of mQTL data from two independent cohorts: Brisbane System Genetics (BSGS) and Lothian Birth Cohorts (LBC).

\*\*\*\* Meta-analysis of mQTL data from three independent cohorts [Hanon et al., Jaffe et al. and ROS/MAP (Hannon et al., 2016; Jaffe et al., 2016; Ng et al., 2017)] by MeCS

247

#### 248 2.5. Gene set enrichment analysis

Our aim is to uncover pathways that are associated with NPSUD. For this purpose, we tested for pathway enrichment in XWAS signals. We performed two separate Functional Mapping and Annotation (FUMA) (v1.41) (Watanabe et al., 2017) pathway analyses using genes with suggestive signals from: i) TWAS and PWAS combined and ii) MWAS only. We included genes with suggestive adjusted p-values () in query gene lists for FUMA analyses assumed a possible universe of 54,619 coding and non-coding genes (protein coding, long non-coding RNA, noncoding RNA and processed transcripts). Due to the complexity of the MHC region, we chose the

option for excluding genes from this region in FUMA analyses. To adjust for multiple testing, we
assessed pathway significance using the False Discovery Rate (FDR) procedure (q-value < 0.05)</li>
(Benjamini and Hochberg, 1995).

259

260 2.6 Joint NPSUD concordance analysis of TWAS and MWAS gene signals

261 To increase the statistical power for the prioritization of genes in underpowered NPSUD and 262 tissues (such as brain), we used a multi-trait and multi-tissue approach. Therefore, we conducted 263 a joint trait concordance analysis using Primo (R package for Integrative Multi-Omics association 264 analysis) (Gleason et al., 2020) within the more powerful XWAS paradigms (TWAS and MWAS). 265 We did not jointly analyze PWAS because brain results were too sparse. We used Primo because 266 it was designed to jointly analyze summary statistics from multiple studies while adjusting for the 267 correlation between datasets (e.g., due to sample overlapping). Gene-level adjusted p-values from 268 SMR analyses were used as input for the joint trait and tissue concordance analyses. If a gene had 269 multiple p-values then the Cauchy method (Liu et al., 2019) was used to combine these p-values 270 to have one p-value for the gene. Because Primo requires the estimated proportion of statistics 271 (alt props) coming from the alternative distribution, we exhaustively tested different values for 272 this parameter. We also estimated it directly from the data using a mixture of two distributions. 273 This parameter was critical because more significant results were identified when larger values of alt probs were used. We finally decided to set alt probs= $10^{-3}$  which was also suggested in the 274 275 Primo paper (Gleason et al., 2020). For prioritization purposes, we considered genes with posterior 276 probabilities (PP) > 0.95 as significant.

277

Besides increasing signal detection in the brain, the joint analysis might open the avenue for further investigations. For instance, blood and brain concordant signals might be further studied to be used as proxies for the brain pathology of NPSUD. It is possible that such blood markers might also have an impact on the diagnosis/prognosis of NPSUD, i.e., concordant XWAS signals might have translational implications.

283

284 **Results** 



285

286 Figure 2. Miami plot [Manhattan blood (above)-brain (below) bi-plot] of TWAS adjusted p-values  $(P'_{SMR})$  for investigated neuropsychiatric and substance use disorders. The upper part of the plot 287 288 is for the blood and the lower part is for the brain. The red horizontal line denotes Bonferroni 289 significance threshold. For visualization, we labeled the signals by their affiliated HUGO gene 290 name and the direction of the SMR effect estimate on the trait shown in parentheses. AUD: 291 Alcohol Use Disorder BIP: Bipolar Disorder OD: Opioid Dependence/Use Disorder ASD: Autism 292 Spectrum Disorder SCZ: Schizophrenia ADHD: Attention Deficit and Hyperactivity Disorder 293 CUD: Cannabis Use Disorder MDD: Major Depression PTSD: Post-traumatic stress disorder. 294

In this section, we provide a selection of the common and shared XWAS results. Due to the strong signals in MHC region making the visualization of other findings difficult, we omitted this region from the plots of results coming from univariate TWAS and PWAS analyses (Figure 1 and 2). Details on MHC signals for these two paradigms were provided in Supplementary Figures 1 and 2. All univariate XWAS results collated by paradigm are available in Supplementary data files.

- 301
- 302 TWAS results

Blood and brain TWAS for BIP, SCZ and MDD yielded the highest number of significant TWAS
signals (Figure 2 and Supplementary Figure 1). These disorders share many common signals,
especially in the Major Histocompatibility Complex (MHC) region on chromosome 6 (25-35
Mbps), e.g., *BTN3A2* and *C4A*, which were concordant (i.e., significant and with the same sign for
effect size) between blood and brain. Other shared signals between three disorders were *ATF6B*, *C4A*, *FLOT1*, *IER3*, *LINC00243*, *TRIM10*, *TUBB*, *TNXA*, *ZNF602P* and *ZSCAN12P1*, in blood
and, *OR2B8P*, *ZKSCAN8P1* and *ZSCAN16-AS1* in brain.

310

Among substance use disorders (SUD), AUD showed significant signals in blood (*NRBP1*, *PPP4C* and *YPEL3*) and brain (*LINC01833*). For CUD, *HYAL3* and *NAA80* on chromosome 3 were significant signals and with concordant direction of effect between blood and brain. CUD also had significant blood-only signals on chromosome 10 in *ENO4* and *SHTN1*. However, robust signals were not detected for OD.

317 For ADHD, there were three significant signals from blood (AL139289.1, AP006621.1 and MED8-

AS1) and two from brain (*MED8* and *TIE1*). For ASD, there were two significant signals on chromosome 22 (*KIZ* and *XRN2*), with *KIZ* also being suggestive in brain. We observed signals

320 for PTSD on chromosome 17, some of which had concordant direction of effect between blood

and brain (e.g., *AC005829.23* and *KANSL1-AS1*). PTSD results also yielded a blood-brain
concordant signal for *KYAT3*.

323



Figure 3. Miami plot [Manhattan blood(above)-brain (below) bi-plot] of PWAS adjusted p-values ( $P'_{SMR}$ ) for investigated neuropsychiatric and substance use disorders. For details and background see Figure 2 legend.

328

324

## 329 **PWAS results**

When compared to TWAS, there was a lower number of PWAS significant signals (Figure 3 and Supplementary Figure 2). This is expected because PWAS had a lower number of probes tested and lower sample for reference panels, especially for brain tissue. For instance, we did not identify any significant blood or brain PWAS signals for OD, ASD or CUD. Similar to TWAS - BIP, SCZ and MDD yielded common signals in MHC regions for blood (*BTN3A3*, *BTN3A1* and *MICB* - see also Supplementary Figure 2 for more details). *NEK4* was a brain only signal shared between SCZ and BIP.

- 337
- 338 For PTSD, significant brain signals were in KYAT3 (detected also in TWAS), KHK, GPX1, MICB
- and CTNND1 (that is also common signal between SCZ and MDD). Among these, only KYAT3

- 340 was blood-brain concordant for the direction of effect. Some notable disease specific signals were
- 341 for ADH1C and ADH1B in AUD blood and TIE1 in ADHD blood PWAS (which was also
- 342 significant in ADHD brain TWAS).
- 343



344

Figure 4. Miami plot [Manhattan blood (above)-brain (below) bi-plot] of MWAS adjusted pvalues ( $P'_{SMR}$ ) for investigated NPSUD. For details and background, see Figure 2 legend.

348

# 349 MWAS results

Notably, biologically significant signals were detected, e.g., *ADH1C* for AUD in blood. Similar to TWAS and PWAS, we found that BIP, SCZ and MDD had more significant signals than the remaining disorders (Figure 4 and Supplementary Files). Again, the largest blood-brain concordant signals that were common between BIP, SCZ and MDD were in the MHC region, such as, *ZSCAN12L1, BTN3A2, H2AC13, ZNF389* for brain and *VARS2, TUBB, TRIM27, TRIM31,* 

355 DPCR1, TRIM15, DDR1, GTF2H4, TRIM40, H2AC13, TRIM26, PBX2, HIST1H4D, SFTA2,
356 BTN3A2, HCG9, HLA-B and MSH5 for blood.

357

As in PWAS, there were no significant signals for OD or ASD. For CUD, *SLC38A3* was a bloodbrain concordant signal. ADHD yielded two significant signals on chromosome 1 (*Clorf84* in blood and *KDM4A* in brain). For PTSD, there were significant signals for *GMPPB*, *SCAND3*, *Cllorf31*, *FURIN* and *MAPT* in blood. Among these, *MAPT* and *Cllorf31* were also concordant between blood and brain. Other leading PTSD brain signals were *AMIGO3*, cg05913906 and *FES*.

363

#### 364 Gene set enrichment analysis results

365 In this section, we highlighted some of the more interesting signals from FUMA gene set 366 enrichment. More detailed results can be found in Supplementary Figures 3-33 and in 367 Supplementary Tables 2 and 3. Consistent with most other XWAS results, there were no 368 significant findings for OD and CUD. As expected, i) SCZ yielded the highest number of signals 369 (due to its larger sample size in GWAS) and ii) alcohol metabolism pathways showed significant 370 enrichments for AUD. For BIP, the combined TWAS and PWAS prioritized genes were 371 significantly enriched in non-genomic actions of the 1,25 dihydroxyvitamin D3 gene set (PLCB3, 372 *PRKCB*, *PRKCA* and *CD40*) (q-value =  $3.81 \times 10^{-2}$ ) (Supplementary Figure 10). Another BIP signal 373 was GWAS catalog gene enrichment for plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid) (*MYRF*, *TMEM258* and *FADS1*) (q-value =  $1.00 \times 10^{-3}$ ) (Supplementary Figure 12). 374 375 For the same disorder, GO HYALURONAN METABOLIC PROCESS (ITIH1, ITIH3 and 376 *ITIH4*) (q-value =  $5.67 \times 10^{-3}$ ) was the most significant Gene Ontology (GO) terms in the Biological 377 Process category (Supplementary Figure 13). For more details, refer to Supplementary Tables 2 378 and 3. Peptidase related GO terms were shared signals between BIP, MDD and SCZ 379 (Supplementary Figures 34-35). Also, neuron related pathways (GO\_SYNAPSE\_PART, 380 GO\_PRESYNAPSE and GO\_POST\_SYNANSE) were significant enrichment for MDD 381 (Supplementary Figures 34 and 35).

382

In the MWAS only analysis, again SCZ yielded the most signals. Metabolism of alpha-linolenic acid (omega-3) was one of the significant gene sets for BIP blood MWAS (*FADS2, FADS1* and *MIR1908*) (q-value =  $3.24 \times 10^{-4}$ ) (Supplementary Figure 33). BIP and SCZ shared a signal for

- cation ion transport related gene sets (GO\_CATION\_TRANSPORT and
  GO\_DIVALENT\_INORGANIC\_CATION\_TRANSPORT) (Supplementary Figure 37). See
  Supplementary Tables 4 and 5 for details.
- 389

## 390 Joint analysis for both i) NPSUD and ii) blood and brain



391

Figure 5. Results of the joint trait concordance analysis for TWAS. The top twenty-five genes are
shown as ranked by the sum of the posterior probabilities (PPs) within brain tissue for disorders:
Attention deficit and hyperactivity disorder (ADHD), Autism spectrum disorder (ASD), Alcohol
use disorder (AUD), Bi-polar disorder (BIP), Major depressive disorder (MDD), Post-traumatic
stress disorder (PTSD) and Schizophrenia (SCZ).

397

398 TWAS/MWAS results were jointly analyzed for seven NPSUD (Figure 5), excluding the 399 underpowered OD and CUD due to poor distributions of XWAS p-values vs Primo PPs.

400 We observed gene signals (PP>0.95) that are shared between many NPSUD and between blood

401 and brain (Figure 5). ZDHHC5 was the most shared signal between blood and brain and five

402	NPSUD (ADHD, AUD, MDD, PTSD and SCZ). There is a cluster of genes that is also shared only
403	between ASD, PTSD and SCZ, e.g., LRRC37A2, KANSL1-AS1, MAPK8IP1P1, MAPK8IP1P2 and
404	AC005829.1. BIP and SCZ also share a number of signals (NEK4, GNL3, NMB, GLYCTK,
405	AC006252.1 and GOLGA2P7).
406	However, there were also disease specific genes, e.g., i) AP006621.3 and PIDD1 for ADHD, ii)
407	ADD3, LMAN2L and PLEC for BIP, iii) KYAT3 and PLEKHM1 for PTSD, iv) PCCB and

408 *GATAD2A* for SCZ and v) *LINC02803* for MDD. (Detailed in Supplementary Table 6)

409

410 While often there were very similar pattern of shared TWAS signals between blood and brain,

411 there were also brain specific signals. For instance, *BRD2*, *FURIN* and *ZSCAN16-AS1* were such

412 brain only signals that are shared among many disorders. [Note that FURIN was successfully

413 tested, via CRISPR/Cas9 experiment on isogenic human induced pluripotent cell, for the allelic

414 effect on its gene expression of the SNP with the largest SCZ signal in the region (Schrode et al.,

415 2019).] There were also both disease and brain specific signals, e.g., *FTCDNL1* for SCZ observed

416 only in brain. For more disease/tissue specific signals, please see also Supplementary Table 6.



417

Figure 6. Results of joint trait concordance analysis for MWAS. The top twenty-five genes
(excluding probes not mapped to a gene name as per Illumina annotation) are shown and ranked
by sum of brain PPs for all disorders.

421

For MWAS, we often observed the same pattern of shared signals between blood and brain. Among the largest signals (ranked by the sum of PP in brain), *C11orf31*, *MED19* and *FURIN* were shared among ADHD, AUD, BIP, MDD, PTSD and SCZ (Figure 6). *GATAD2A* stood out as shared brain specific signal among ADHD, ASD, BIP, PTSD and SCZ. *RERE* was shared among AUD, MDD, PTSD and SCZ, which was one of the eGenes for a cis-eQTL associated with SCZ that showed allele specific effect via the chromatin interaction (Zhang et al., 2020). For more details about results, see Supplementary Table 7.

#### 429 **Discussion**

430 To provide biological context to GWAS findings, we performed XWAS analyses using the SMR 431 was performed. These analyses uncovered putative risk genes by inferring the association between 432 the transcriptome/proteome/methylome and NPSUD. We subsequently identified molecular 433 pathways associated with NPSUD via gene set enrichment analyses of genes that yielded XWAS 434 suggestive signals. To improve signal detection power for underpowered traits and brain tissue, 435 we also performed a joint concordance analysis of all traits and tissues within the two adequately 436 powered XWAS paradigms (TWAS and MWAS) were performed. The results of this work suggest 437 possible components of the treatment regimen for certain NPSUD, e.g., the possible implication 438 of vitamins (B<sub>6</sub> and D) and omega-3 pathways for some of these disorders.

439

440 Our analyses replicated biologically relevant and previous significant findings. Among the 441 biologically relevant ones, we note that the common signal in AUD between blood PWAS and 442 MWAS was ADH1C, which codes for alcohol dehydrogenase enzyme that metabolizes the 443 alcohol. It was also implicated as a significant loci in various GWAS of alcohol related phenotypes 444 (Gelernter et al., 2014; Clarke et al., 2017; Kranzler et al., 2019). We also replicated findings from 445 Dall'Aglio et al. (Dall'Aglio et al., 2021), in which NEGR1 was found to be a signal for MDD as 446 it was the second most significant gene in our MDD blood TWAS. Similar to our TWAS results, 447 BTN3A2 and RPL31P12 were significant findings in a previous MDD brain TWAS from Yang et 448 al. (Yang et al., 2021b).

449

450 In our joint TWAS concordance analyses, ZDHHC5 was the shared signal between all NPSUD 451 except for ASD and BIP (Figure 5). This gene was previously found to be a shared blood TWAS 452 signal between MDD and SCZ (Reay and Cairns, 2020). In the same paper, some of our other 453 XWAS signals shared between BIP and SCZ (e.g., NEK4, GNL3 and NMB) were also reported as 454 shared TWAS signals in blood. Another shared signal between SCZ, BIP and AUD was INO80E 455 which was previously indicated as one of the top ten shared signals between SCZ and AUD 456 (Johnson et al., 2021). A common blood-brain MWAS signal for AUD, MDD, PTSD and SCZ 457 from the Primo joint analyses was *RERE*. It was one of the eGenes for a cis-eQTL showing allele 458 specific effect via the chromatin interaction (Zhang et al., 2020). The same gene was also

459 implicated as a significant gene in SMR analysis in the recent PGC SCZ GWAS (Trubetskoy et460 al., 2022).

461

462 We compared our joint trait concordance analysis findings for SCZ (brain TWAS+MWAS or brain 463 TWAS only) with PGC3 SCZ GWAS findings. There were common genes identified as significant 464 (PP>0.95) in our brain tissue results (TWAS+MWAS) and those found in the list of significant 465 replication and discovery loci (see Supplementary Table 8) in PGC3 SCZ GWAS, such as, BTN3A2, FURIN, GATAD2A, GNL3, INO80E, KANSL1-AS1 and NEK4. However, we found 466 467 significant signals for AC005829.1, BRD2, C11orf31, C6orf15, DND1P1, MAPK8IP1P1 and 468 ZNF602P, which were not found as significant in the above PGC3 SCZ gene list. There are also 469 common genes between our brain tissue TWAS results (from the joint analysis) and the list of 470 genes in PGC SCZ that were prioritized based on the SMR analysis only. Those genes are *INO80E*, 471 GATAD2A, PCCB and FURIN. However, our brain results include significant findings that were 472 not identified in PGC3 SCZ, such as BRD2, GNL3, KANSL1-AS1, NEK4 and ZDHHC5. (For 473 details see Supplementary Table 8)

474

475 The MHC region is a well-known region associated with some of the NPSUD, e.g., SCZ (Corvin 476 and Morris, 2014). Our joint XWAS analyses strongly support this assertion for SCZ, BIP, PTSD 477 and MDD. For instance, BTN3A2 was the leading TWAS signal for BIP, MDD and SCZ. Also, 478 C4A, thought to be implicated in synaptic pruning (Sekar et al., 2016), was a shared brain TWAS 479 signal for BIP, MDD, PTSD and SCZ (Figure 5). Similarly, *MICB* was shared between AUD, BIP, 480 MDD, PTSD and SCZ in brain MWAS (Figure 6). Its possible involvement in NPSUD was also 481 supported by empirical transcriptomic evidence. Research showed that *MICB* is part of a molecular 482 network interacting with the differentially expressed genes in Brodmann's area 9 region of 483 individuals with MDD (Scarr et al., 2019).

484

Beside many common signals between NPSUD, there are also some that are disease specific. For PTSD, we observed specific signals for TWAS/PWAS in a cluster of genes on chromosome 17 and *KYAT3* on chromosome 1. *KYAT3* was the strongest signal for PTSD brain PWAS. It was reported as a TWAS signal for reexperiencing a PTSD symptom cluster (Pathak et al., 2022). A

489 GWAS on social anxiety also found SNP that is downstream of KYAT3 to be significant (Stein et490 al., 2017).

491

492 AUD specific TWAS signals were on chromosome 2 for NRBP1 and SNX17. A meta-analysis of 493 Alcohol Use Disorders Identification Test (AUDIT) showed that index SNP for GCKR overlap 494 also with the SNX17 (Sanchez-Roige et al., 2019). This same gene was also found significant (p-495 value =  $1.18 \times 10^{-6}$ ; brain caudate basal ganglia) in TWAS of substance use disorder (Hatoum et al., 496 2022). For ADHD, TIE1 (chromosome 1) is a TWAS/PWAS signal that was not found in other 497 NPSUD. This gene is coding for tyrosine kinase and it was found as significant in PTSD TWAS 498 (Liao et al., 2019) and ADHD TWAS (Chen et al., 2022). For CUD, we also identified concordant 499 blood-brain TWAS signals on chromosome 3, e.g., HYAL3 and NAA80. In another TWAS analysis 500 using the same CUD GWAS (Table 1), they also found HYAL3 was found to be significant 501 (Johnson et al., 2020). Previously, expression of NAA80 in brain (anterior cingulate cortex) was 502 associated with the genome-wide significant variant rs2777888 in meta-analyzed European 503 ancestry PTSD GWAS (Gelernter et al., 2019).

504

505 Since blood and brain cis-xQTL were known to overlap, this was used to improve the discovery 506 power for brain XWAS analyses through the joint analysis of both tissues. The joint analyses found 507 many candidate risk genes that are concordant in direction of effect for both tissues. The blood 508 XWAS of these concordant genes might be useful for future development of NPSUD multivariate 509 blood biomarkers that might be used for diagnosis, prognosis and possible treatment of these 510 disorders.

511

512 Supplements such as vitamins and omega-3 have been tested (with varying success rates) as 513 treatment for NPSUD (Firth et al., 2019). Previous investigations in blood indicated that the 514 deficiency (Anglin et al., 2013) and supplementation (Sarris et al., 2016) of vitamin D might 515 increase/decrease the risk for MDD. Other studies did not find any effect of vitamin D 516 supplementation on MDD (Marsh et al., 2017) and depression in older adults (Okereke et al., 517 2020). A most recent GWAS of polyunsaturated and monounsaturated fatty acids showed a 518 significant gene set enrichment of GWAS catalog genes in Bipolar I and II (Francis et al., 2022). 519 Omega-3 was also found to likely lower MDD risk (Mocking et al., 2016). It is not clear if these

non-genetic/non-MR studies did eliminate most confounders. However, most confounders are
eliminated by using mendelian randomization methods, such as SMR that was used in this work.

522

523 While we did not uncover any vitamin associated pathway or gene signal for MDD, our analyses 524 indicated link between such supplements and other NPSUD. For instance, BIP TWAS and PWAS 525 prioritized genes showed significant gene set enrichment for the vitamin D3 pathway 526 (Supplementary Figure 10). For BIP, we also found significant gene set enrichment in omega-3 associated gene sets in combined T/PWAS (Supplementary Figure 11) and MWAS only 527 528 (Supplementary Figure 36) FUMA analyses. KYAT3 signal found in PTSD T/PWAS suggests a 529 possible etiological role of vitamin  $B_6$  in this disease. Based on these findings, more clinical 530 research evidence is needed to test these molecules as a secondary component of the treatment 531 regimen: i) vitamin D and omega-3 modest supplementation for BIP and ii) vitamin B<sub>6</sub> (or B 532 complex) for PTSD.

533

534 The importance of this study is five-fold. First, this is the most powerful XWAS study of NPSUD 535 because we integrated the largest available xQTL reference data and NPSUD GWAS. Second, we 536 extended these most powerful gene-level XWAS inferences to pathway level, which suggested 537 some novel avenues for treatment. Third, we further increased the detection power for 538 underpowered trait and tissues via multi-trait multi-tissue joint analyses. Fourth, the joint analyses 539 uncovered blood-brain concordant XWAS signal that, in the future, might form the basis for the 540 development of (multivariate) blood biomarkers for diagnosis/prognosis. Fifth, these joint analyses 541 are the first formal attempt to uncover common signals for multiple disorders and those specific to 542 a single one.

543

## 544 Limitations of the study

 Although we applied the HEIDI test, it is not likely that SMR completely eliminates the horizontal pleiotropy. For instance, a SNP might be xQTL for multiple genes, which violates the assumption that the SNP effect on the trait is mediated only through the tested gene. However, we believe that gene set/pathway inferences are likely to mitigate the confounding effect of this phenomenon from gene-level analysis.

550	2.	While Primo can adjust for the correlations between multiple different studies, it does not		
551		correct for the correlation between genes (e.g., which can happen due to the linkage		
552		disequilibrium of variants). Thus, future studies need to validate the identified genes.		
553	3.	Reference brain pQTL has lower sample sizes than the blood pQTL data. This resulted in		
554		fewer significant signals for brain PWAS.		
555	4.	Some reference xQTL data (e.g., brain proteome) are enriched in individuals with certain		
556		neurological disorders.		
557	5.	We used 1000 Genome phase 3 as a reference LD panel that might not be an exact match		
558		for the LD patterns from the GWAS cohort. By adjusting $P_{SMR}$ , we eliminated the inflation		
559		of $P_{HEIDI}$ , signals due to any cohort-panel LD mismatch.		
560	6.	Due to extended and irregular LD patterns, findings in certain regions (e.g., MHC) should		
561		be interpreted with care.		
562	7.	Since we only included xQTL reference data obtained from bulk tissue, any cell type		
563		specific information was not presented in our findings.		
564 565	Data a	vailability statement		
566	All pul	blicly available data used in this study were listed in Supplementary Table 1. All the data		
567	generated in this study will be open to public when the manuscript is published.			
568	-			
569	Autho	rs' Contributions		
570	HG co	mpleted the XWAS analysis and data visualization. THN conducted the joint trait analysis.		
571	CC co	ntributed GWAS data. VIV, BPR and SAB supervised the study design. All authors		
572	contributed to the preparation of the manuscript.			
573				
574	Fundi	ng		
575	Research in this work was funded by AA022537 (Huseyin Gedik, Brian P. Riley, and Silviu-Alin			
576	Bacanı	a), R01MH118239 and R01DA052453 (Vladimir I. Vladimirov and Silviu-Alin Bacanu).		
577 578	Confli	ct of Interest		
579	Author	rs do have any conflict of interest to report.		
580 581 582	Refere	ences		

- Aberg, K. A., Dean, B., Shabalin, A. A., Chan, R. F., Han, L. K. M., Zhao, M., et al. (2020).
  Methylome-wide association findings for major depressive disorder overlap in blood and
  brain and replicate in independent brain samples. *Mol Psychiatry* 25, 1344–1354. doi:
  10.1038/s41380-018-0247-6.
- Anglin, R. E. S., Samaan, Z., Walter, S. D., and McDonald, S. D. (2013). Vitamin D deficiency
   and depression in adults: systematic review and meta-analysis. *The British Journal of Psychiatry* 202, 100–107. doi: 10.1192/bjp.bp.111.106666.
- Aygün, N., Elwell, A. L., Liang, D., Lafferty, M. J., Cheek, K. E., Courtney, K. P., et al. (2021).
  Brain-trait-associated variants impact cell-type-specific gene regulation during
  neurogenesis. *The American Journal of Human Genetics* 108, 1647–1668. doi:
  10.1016/j.ajhg.2021.07.011.
- Bae, Y. E., Wu, L., and Wu, C. (2021). InTACT: An adaptive and powerful framework for joint tissue transcriptome-wide association studies. *Genet Epidemiol*. doi: 10.1002/gepi.22425.
- Barbeira, A. N., Dickinson, S. P., Bonazzola, R., Zheng, J., Wheeler, H. E., Torres, J. M., et al.
  (2018). Exploring the phenotypic consequences of tissue specific gene expression
  variation inferred from GWAS summary statistics. *Nat Commun* 9, 1825. doi:
  10.1038/s41467-018-03621-1.
- Barbeira, A. N., Pividori, M., Zheng, J., Wheeler, H. E., Nicolae, D. L., and Im, H. K. (2019).
   Integrating predicted transcriptome from multiple tissues improves association detection.
   *PLOS Genetics* 15, e1007889. doi: 10.1371/journal.pgen.1007889.
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
   Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B* (*Methodological*) 57, 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x.
- Brennand, K., Simone, A., Tran, N., and Gage, F. (2012). Modeling psychiatric disorders at the
  cellular and network levels. *Mol Psychiatry* 17, 1239–1253. doi: 10.1038/mp.2012.20.
- Bryois, J., Calini, D., Macnair, W., Foo, L., Urich, E., Ortmann, W., et al. (2022). Cell-typespecific cis-eQTLs in eight human brain cell types identify novel risk genes for
  psychiatric and neurological disorders. *Nat Neurosci* 25, 1104–1112. doi:
  10.1038/s41593-022-01128-z.
- Buenrostro, J. D., Wu, B., Litzenburger, U. M., Ruff, D., Gonzales, M. L., Snyder, M. P., et al.
  (2015). Single-cell chromatin accessibility reveals principles of regulatory variation. *Nature* 523, 486–490. doi: 10.1038/nature14590.
- Chen, X., Yao, T., Cai, J., Zhang, Q., Li, S., Li, H., et al. (2022). A novel cis-regulatory variant
  modulating TIE1 expression associated with attention deficit hyperactivity disorder in
  Han Chinese children. *Journal of Affective Disorders* 300, 179–188. doi:
  10.1016/j.jad.2021.12.066.

619 Clarke, T.-K., Adams, M. J., Davies, G., Howard, D. M., Hall, L. S., Padmanabhan, S., et al. 620 (2017). Genome-wide association study of alcohol consumption and genetic overlap with 621 other health-related traits in UK Biobank (N=112 117). Mol Psychiatry 22, 1376–1384. 622 doi: 10.1038/mp.2017.153. 623 Consortium, T. Gte. (2020). The GTEx Consortium atlas of genetic regulatory effects across 624 human tissues. Science. Available at: 625 http://www.science.org/doi/abs/10.1126/science.aaz1776 [Accessed September 6, 2021]. 626 Corvin, A., and Morris, D. W. (2014). Genome-wide Association Studies: Findings at the Major 627 Histocompatibility Complex Locus in Psychosis. Biological Psychiatry 75, 276–283. doi: 628 10.1016/j.biopsych.2013.09.018. Dall'Aglio, L., Lewis, C. M., and Pain, O. (2021). Delineating the Genetic Component of Gene 629 630 Expression in Major Depression. *Biological Psychiatry* 89, 627–636. doi: 631 10.1016/j.biopsych.2020.09.010. 632 Demontis, D., Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E., et al. (2019). 633 Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity 634 disorder. Nat Genet 51, 63-75. doi: 10.1038/s41588-018-0269-7. 635 Edwards, S. L., Beesley, J., French, J. D., and Dunning, A. M. (2013). Beyond GWASs: 636 Illuminating the Dark Road from Association to Function. The American Journal of 637 Human Genetics 93, 779–797. doi: 10.1016/j.ajhg.2013.10.012. 638 Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, 639 E. L., et al. (2021). Large-scale integration of the plasma proteome with genetics and 640 disease. Nature Genetics 53, 1712–1721. doi: 10.1038/s41588-021-00978-w. 641 Firth, J., Teasdale, S. B., Allott, K., Siskind, D., Marx, W., Cotter, J., et al. (2019). The efficacy 642 and safety of nutrient supplements in the treatment of mental disorders: a meta-review of 643 meta-analyses of randomized controlled trials. World Psychiatry 18, 308-324. doi: 644 10.1002/wps.20672. 645 Francis, M., Sun, Y., Xu, H., Brenna, J. T., and Ye, K. (2022). Fifty-one novel and replicated 646 GWAS loci for polyunsaturated and monounsaturated fatty acids in 124,024 Europeans. 647 2022.05.27.22275343. doi: 10.1101/2022.05.27.22275343. 648 Gamazon, E. R., Wheeler, H. E., Shah, K. P., Mozaffari, S. V., Aquino-Michaels, K., Carroll, R. 649 J., et al. (2015). A gene-based association method for mapping traits using reference 650 transcriptome data. Nat Genet 47, 1091–1098. doi: 10.1038/ng.3367. 651 Gelernter, J., Kranzler, H. R., Sherva, R., Almasy, L., Koesterer, R., Smith, A. H., et al. (2014). 652 Genome-wide association study of alcohol dependence:significant findings in Africanand European-Americans including novel risk loci. Mol Psychiatry 19, 41-49. doi: 653 654 10.1038/mp.2013.145.

655 Gelernter, J., Sun, N., Polimanti, R., Pietrzak, R., Levey, D. F., Bryois, J., et al. (2019). Genome-656 wide association study of post-traumatic stress disorder reexperiencing symptoms in 657 >165,000 US veterans. Nat Neurosci 22, 1394–1401. doi: 10.1038/s41593-019-0447-7. 658 Gleason, K. J., Yang, F., Pierce, B. L., He, X., and Chen, L. S. (2020). Primo: integration of 659 multiple GWAS and omics QTL summary statistics for elucidation of molecular 660 mechanisms of trait-associated SNPs and detection of pleiotropy in complex traits. Genome Biol 21, 1-24. doi: 10.1186/s13059-020-02125-w. 661 662 Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., et al. (2010). Aptamer-Based 663 Multiplexed Proteomic Technology for Biomarker Discovery. PLOS ONE 5, e15004. doi: 664 10.1371/journal.pone.0015004. 665 Gold, L., Walker, J. J., Wilcox, S. K., and Williams, S. (2012). Advances in human proteomics at high scale with the SOMAscan proteomics platform. New Biotechnology 29, 543–549. 666 667 doi: 10.1016/j.nbt.2011.11.016. 668 Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H., et al. (2019). 669 Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 670 51, 431–444. doi: 10.1038/s41588-019-0344-8. Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B. W. J. H., et al. (2016). Integrative 671 672 approaches for large-scale transcriptome-wide association studies. Nat Genet 48, 245-673 252. doi: 10.1038/ng.3506. 674 Hammerschlag, A. R., Byrne, E. M., Agbessi, M., Ahsan, H., Alves, I., Andiappan, A., et al. 675 (2020). Refining Attention-Deficit/Hyperactivity Disorder and Autism Spectrum 676 Disorder Genetic Loci by Integrating Summary Data From Genome-wide Association, 677 Gene Expression, and DNA Methylation Studies. *Biological Psychiatry* 88, 470–479. doi: 678 10.1016/j.biopsych.2020.05.002. 679 Hannon, E., Dempster, E., Viana, J., Burrage, J., Smith, A. R., Macdonald, R., et al. (2016). An 680 integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of 681 genetic associations and differential DNA methylation. Genome Biology 17, 176. doi: 682 10.1186/s13059-016-1041-x. 683 Hatoum, A. S., Colbert, S. M. C., Johnson, E. C., Huggett, S. B., Deak, J. D., Pathak, G., et al. 684 (2022). Multivariate genome-wide association meta-analysis of over 1 million subjects 685 identifies loci underlying multiple substance use disorders. *medRxiv*, 2022.01.06.22268753. doi: 10.1101/2022.01.06.22268753. 686 Howard, D. M., Adams, M. J., Clarke, T.-K., Hafferty, J. D., Gibson, J., Shirali, M., et al. (2019). 687 688 Genome-wide meta-analysis of depression identifies 102 independent variants and 689 highlights the importance of the prefrontal brain regions. Nat Neurosci 22, 343–352. doi: 10.1038/s41593-018-0326-7. 690

- Howard, D. M., Pain, O., Arathimos, R., Barbu, M. C., Amador, C., Walker, R. M., et al. (2022).
  Methylome-wide association study of early life stressors and adult mental health. *Human Molecular Genetics* 31, 651–664. doi: 10.1093/hmg/ddab274.
- Hu, Y., Li, M., Lu, Q., Weng, H., Wang, J., Zekavat, S. M., et al. (2019). A statistical framework
  for cross-tissue transcriptome-wide association analysis. *Nat Genet* 51, 568–576. doi:
  10.1038/s41588-019-0345-7.
- Jaffe, A. E., Gao, Y., Deep-Soboslay, A., Tao, R., Hyde, T. M., Weinberger, D. R., et al. (2016).
   Mapping DNA methylation across development, genotype and schizophrenia in the
   human frontal cortex. *Nat Neurosci* 19, 40–47. doi: 10.1038/nn.4181.
- Johnson, E. C., Demontis, D., Thorgeirsson, T. E., Walters, R. K., Polimanti, R., Hatoum, A. S.,
  et al. (2020). A large-scale genome-wide association study meta-analysis of cannabis use
  disorder. *The Lancet Psychiatry* 7, 1032–1045. doi: 10.1016/S2215-0366(20)30339-4.
- Johnson, E. C., Kapoor, M., Hatoum, A. S., Zhou, H., Polimanti, R., Wendt, F. R., et al. (2021).
  Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder. *Psychological Medicine*, 1–9. doi: 10.1017/S003329172100266X.
- Kapoor, M., Chao, M. J., Johnson, E. C., Novikova, G., Lai, D., Meyers, J. L., et al. (2021).
  Multi-omics integration analysis identifies novel genes for alcoholism with potential
  overlap with neurodegenerative diseases. *Nat Commun* 12, 5071. doi: 10.1038/s41467021-25392-y.
- Kelley, K. W., Nakao-Inoue, H., Molofsky, A. V., and Oldham, M. C. (2018). Variation among
  intact tissue samples reveals the core transcriptional features of human CNS cell classes. *Nat Neurosci* 21, 1171–1184. doi: 10.1038/s41593-018-0216-z.
- Kranzler, H. R., Zhou, H., Kember, R. L., Vickers Smith, R., Justice, A. C., Damrauer, S., et al.
  (2019). Genome-wide association study of alcohol consumption and use disorder in
  274,424 individuals from multiple populations. *Nat Commun* 10, 1499. doi:
  10.1038/s41467-019-09480-8.
- Lee, P. H., Anttila, V., Won, H., Feng, Y.-C. A., Rosenthal, J., Zhu, Z., et al. (2019). Genomic
  Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric
  Disorders. *Cell* 179, 1469-1482.e11. doi: 10.1016/j.cell.2019.11.020.
- Liao, C., Laporte, A. D., Spiegelman, D., Akçimen, F., Joober, R., Dion, P. A., et al. (2019).
  Transcriptome-wide association study of attention deficit hyperactivity disorder identifies
  associated genes and phenotypes. *Nat Commun* 10, 4450. doi: 10.1038/s41467-01912450-9.
- Liu, Y., Chen, S., Li, Z., Morrison, A. C., Boerwinkle, E., and Lin, X. (2019). ACAT: A Fast and
   Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies.
   *The American Journal of Human Genetics* 104, 410–421. doi:
   10.1016/j.ajhg.2019.01.002.

- Mancuso, N., Freund, M. K., Johnson, R., Shi, H., Kichaev, G., Gusev, A., et al. (2019).
  Probabilistic fine-mapping of transcriptome-wide association studies. *Nat Genet* 51, 675–682. doi: 10.1038/s41588-019-0367-1.
- Marsh, W. K., Penny, J. L., and Rothschild, A. J. (2017). Vitamin D supplementation in bipolar
  depression: A double blind placebo controlled trial. *Journal of Psychiatric Research* 95,
  48–53. doi: 10.1016/j.jpsychires.2017.07.021.
- Marstrand, T. T., and Storey, J. D. (2014). Identifying and mapping cell-type-specific chromatin
   programming of gene expression. *Proceedings of the National Academy of Sciences* 111,
   E645–E654. doi: 10.1073/pnas.1312523111.
- McRae, A. F., Marioni, R. E., Shah, S., Yang, J., Powell, J. E., Harris, S. E., et al. (2018).
  Identification of 55,000 Replicated DNA Methylation QTL. *Sci Rep* 8, 17605. doi: 10.1038/s41598-018-35871-w.
- Mocking, R. J. T., Harmsen, I., Assies, J., Koeter, M. W. J., Ruhé, H. G., and Schene, A. H.
  (2016). Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid
  supplementation for major depressive disorder. *Transl Psychiatry* 6, e756–e756. doi:
  10.1038/tp.2016.29.
- Mullins, N., Forstner, A. J., O'Connell, K. S., Coombes, B., Coleman, J. R. I., Qiao, Z., et al.
  (2021). Genome-wide association study of more than 40,000 bipolar disorder cases
  provides new insights into the underlying biology. *Nat Genet* 53, 817–829. doi:
  10.1038/s41588-021-00857-4.
- Nagpal, S., Meng, X., Epstein, M. P., Tsoi, L. C., Patrick, M., Gibson, G., et al. (2019). TIGAR:
  An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene
  Mapping of Complex Traits. *The American Journal of Human Genetics* 105, 258–266.
  doi: 10.1016/j.ajhg.2019.05.018.
- Ng, B., White, C. C., Klein, H.-U., Sieberts, S. K., McCabe, C., Patrick, E., et al. (2017). An
  xQTL map integrates the genetic architecture of the human brain's transcriptome and
  epigenome. *Nat Neurosci* 20, 1418–1426. doi: 10.1038/nn.4632.
- Nievergelt, C. M., Maihofer, A. X., Klengel, T., Atkinson, E. G., Chen, C.-Y., Choi, K. W., et al.
  (2019). International meta-analysis of PTSD genome-wide association studies identifies
  sex- and ancestry-specific genetic risk loci. *Nat Commun* 10, 4558. doi: 10.1038/s41467019-12576-w.
- Niu, H.-M., Yang, P., Chen, H.-H., Hao, R.-H., Dong, S.-S., Yao, S., et al. (2019).
  Comprehensive functional annotation of susceptibility SNPs prioritized 10 genes for schizophrenia. *Transl Psychiatry* 9, 1–12. doi: 10.1038/s41398-019-0398-5.

# Okereke, O. I., Reynolds, C. F., III, Mischoulon, D., Chang, G., Vyas, C. M., Cook, N. R., et al. (2020). Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. *JAMA* 324, 471–480. doi: 10.1001/jama.2020.10224.

- Ongen, H., Brown, A. A., Delaneau, O., Panousis, N. I., Nica, A. C., and Dermitzakis, E. T.
  (2017). Estimating the causal tissues for complex traits and diseases. *Nat Genet* 49, 1676–1683. doi: 10.1038/ng.3981.
- Owen, M. J., and Williams, N. M. (2021). Explaining the missing heritability of psychiatric disorders. *World Psychiatry* 20, 294–295. doi: 10.1002/wps.20870.
- Pardiñas, A. F., Holmans, P., Pocklington, A. J., Escott-Price, V., Ripke, S., Carrera, N., et al.
  (2018). Common schizophrenia alleles are enriched in mutation-intolerant genes and in
  regions under strong background selection. *Nat Genet* 50, 381–389. doi: 10.1038/s41588018-0059-2.
- Pathak, G. A., Singh, K., Wendt, F. R., Fleming, T. W., Overstreet, C., Koller, D., et al. (2022).
  Genetically regulated multi-omics study for symptom clusters of posttraumatic stress
  disorder highlights pleiotropy with hematologic and cardio-metabolic traits. *Mol Psychiatry* 27, 1394–1404. doi: 10.1038/s41380-022-01488-9.
- Perzel Mandell, K. A., Eagles, N. J., Wilton, R., Price, A. J., Semick, S. A., Collado-Torres, L.,
  et al. (2021). Genome-wide sequencing-based identification of methylation quantitative
  trait loci and their role in schizophrenia risk. *Nat Commun* 12, 5251. doi:
  10.1038/s41467-021-25517-3.
- Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, S., de Jonge, P., et al.
  (2019). Exploring Comorbidity Within Mental Disorders Among a Danish National
  Population. *JAMA Psychiatry* 76, 259–270. doi: 10.1001/jamapsychiatry.2018.3658.
- Polimanti, R., Walters, R. K., Johnson, E. C., McClintick, J. N., Adkins, A. E., Adkins, D. E., et
  al. (2020). Leveraging genome-wide data to investigate differences between opioid use
  vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. *Mol Psychiatry* 25, 1673–1687. doi: 10.1038/s41380-020-0677-9.
- Qi, T., Wu, Y., Fang, H., Zhang, F., Liu, S., Zeng, J., et al. (2022). Genetic control of RNA
  splicing and its distinct role in complex trait variation. *Nat Genet*, 1–9. doi:
  10.1038/s41588-022-01154-4.
- Qi, T., Wu, Y., Zeng, J., Zhang, F., Xue, A., Jiang, L., et al. (2018). Identifying gene targets for
   brain-related traits using transcriptomic and methylomic data from blood. *Nat Commun* 9,
   2282. doi: 10.1038/s41467-018-04558-1.
- Reay, W. R., and Cairns, M. J. (2020). Pairwise common variant meta-analyses of schizophrenia
  with other psychiatric disorders reveals shared and distinct gene and gene-set
  associations. *Transl Psychiatry* 10, 134. doi: 10.1038/s41398-020-0817-7.
- Robins, C., Liu, Y., Fan, W., Duong, D. M., Meigs, J., Harerimana, N. V., et al. (2021). Genetic
  control of the human brain proteome. *The American Journal of Human Genetics* 108,
  400–410. doi: 10.1016/j.ajhg.2021.01.012.

803	Sanchez-Priego, C., Hu, R., Boshans, L. L., Lalli, M., Janas, J. A., Williams, S. E., et al. (2022).
804	Mapping cis-regulatory elements in human neurons links psychiatric disease heritability
805	and activity-regulated transcriptional programs. <i>Cell Reports</i> 39, 110877. doi:
806	10.1016/j.celrep.2022.110877.
807 808 809 810 811	<ul> <li>Sanchez-Roige, S., Palmer, A. A., Fontanillas, P., Elson, S. L., 23andMe Research Team, the Substance Use Disorder Working Group of the Psychiatric Genomics Consortium, Adams, M. J., et al. (2019). Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. <i>Am J Psychiatry</i> 176, 107–118. doi: 10.1176/appi.ajp.2018.18040369.</li> </ul>
812	Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., et al. (2016).
813	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. AJP
814	173, 575–587. doi: 10.1176/appi.ajp.2016.15091228.
815	Scarr, E., Udawela, M., and Dean, B. (2019). Changed cortical risk gene expression in major
816	depression and shared changes in cortical gene expression between major depression and
817	bipolar disorders. <i>Aust N Z J Psychiatry</i> 53, 1189–1198. doi:
818	10.1177/0004867419857808.
819	Schrode, N., Ho, SM., Yamamuro, K., Dobbyn, A., Huckins, L., Matos, M. R., et al. (2019).
820	Synergistic effects of common schizophrenia risk variants. <i>Nature Genetics</i> 51, 1475–
821	1485. doi: 10.1038/s41588-019-0497-5.
822	Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., et al. (2016).
823	Schizophrenia risk from complex variation of complement component 4. <i>Nature</i> 530,
824	177–183. doi: 10.1038/nature16549.
825	Shen, X., Caramaschi, D., Adams, M. J., Walker, R. M., Min, J. L., Kwong, A., et al. (2022).
826	DNA methylome-wide association study of genetic risk for depression implicates antigen
827	processing and immune responses. <i>Genome Medicine</i> 14, 36. doi: 10.1186/s13073-022-
828	01039-5.
829	Spaethling, J. M., Na, YJ., Lee, J., Ulyanova, A. V., Baltuch, G. H., Bell, T. J., et al. (2017).
830	Primary Cell Culture of Live Neurosurgically Resected Aged Adult Human Brain Cells
831	and Single Cell Transcriptomics. <i>Cell Reports</i> 18, 791–803. doi:
832	10.1016/j.celrep.2016.12.066.
833	Stein, M. B., Chen, CY., Jain, S., Jensen, K. P., He, F., Heeringa, S. G., et al. (2017). Genetic
834	risk variants for social anxiety. <i>American Journal of Medical Genetics Part B:</i>
835	<i>Neuropsychiatric Genetics</i> 174, 120–131. doi: 10.1002/ajmg.b.32520.
836	Sugawara, H., Murata, Y., Ikegame, T., Sawamura, R., Shimanaga, S., Takeoka, Y., et al. (2018).
837	DNA methylation analyses of the candidate genes identified by a methylome-wide
838	association study revealed common epigenetic alterations in schizophrenia and bipolar
839	disorder. <i>Psychiatry and Clinical Neurosciences</i> 72, 245–254. doi: 10.1111/pcn.12645.

- Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., et al. (2018).
  Genomic atlas of the human plasma proteome. *Nature* 558, 73–79. doi: 10.1038/s41586-018-0175-2.
- Taraszka, K., Zaitlen, N., and Eskin, E. (2022). Leveraging pleiotropy for joint analysis of
  genome-wide association studies with per trait interpretations. *PLOS Genetics* 18,
  e1010447. doi: 10.1371/journal.pgen.1010447.
- THE BRAINSTORM CONSORTIUM, Anttila, V., Bulik-Sullivan, B., Finucane, H. K., Walters,
  R. K., Bras, J., et al. (2018). Analysis of shared heritability in common disorders of the
  brain. *Science* 360, eaap8757. doi: 10.1126/science.aap8757.
- THE GTEX CONSORTIUM, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young,
  T. R., et al. (2015). The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue
  gene regulation in humans. *Science* 348, 648–660. doi: 10.1126/science.1262110.
- Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T. B., et al.
  (2022). Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* 604, 502–508. doi: 10.1038/s41586-022-04434-5.
- Turley, P., Walters, R. K., Maghzian, O., Okbay, A., Lee, J. J., Fontana, M. A., et al. (2018).
  Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nat Genet* 50, 229–237. doi: 10.1038/s41588-017-0009-4.
- van der Wijst, M., de Vries, D., Groot, H., Trynka, G., Hon, C., Bonder, M., et al. (2020). The
  single-cell eQTLGen consortium. *eLife* 9, e52155. doi: 10.7554/eLife.52155.
- Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M. J., Deelen, P., Zeng, B., et al. (2021).
  Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and
  polygenic scores that regulate blood gene expression. *Nat Genet* 53, 1300–1310. doi:
  10.1038/s41588-021-00913-z.
- Wainberg, M., Sinnott-Armstrong, N., Mancuso, N., Barbeira, A. N., Knowles, D. A., Golan, D.,
  et al. (2019). Opportunities and challenges for transcriptome-wide association studies. *Nat Genet* 51, 592–599. doi: 10.1038/s41588-019-0385-z.
- Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F. C. P., et al. (2018). Comprehensive
  functional genomic resource and integrative model for the human brain. *Science* 362,
  eaat8464. doi: 10.1126/science.aat8464.
- Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional mapping
  and annotation of genetic associations with FUMA. *Nat Commun* 8, 1826. doi:
  10.1038/s41467-017-01261-5.
- Watson, H. J., Yilmaz, Z., Thornton, L. M., Hübel, C., Coleman, J. R. I., Gaspar, H. A., et al.
  (2019). Genome-wide association study identifies eight risk loci and implicates metabopsychiatric origins for anorexia nervosa. *Nat Genet* 51, 1207–1214. doi: 10.1038/s41588019-0439-2.

877	Wingo, T. S., Liu, Y., Gerasimov, E. S., Gockley, J., Logsdon, B. A., Duong, D. M., et al.
878	(2021). Brain proteome-wide association study implicates novel proteins in depression
879	pathogenesis. <i>Nat Neurosci</i> 24, 810–817. doi: 10.1038/s41593-021-00832-6.
880	Wingo, T. S., Liu, Y., Gerasimov, E. S., Vattathil, S. M., Wynne, M. E., Liu, J., et al. (2022).
881	Shared mechanisms across the major psychiatric and neurodegenerative diseases. <i>Nat</i>
882	<i>Commun</i> 13, 4314. doi: 10.1038/s41467-022-31873-5.
883	Wu, Y., Zeng, J., Zhang, F., Zhu, Z., Qi, T., Zheng, Z., et al. (2018). Integrative analysis of
884	omics summary data reveals putative mechanisms underlying complex traits. <i>Nat</i>
885	<i>Commun</i> 9, 918. doi: 10.1038/s41467-018-03371-0.
886	Yang, C., Farias, F. H. G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M. V., et al. (2021a).
887	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins
888	implicated in neurological disorders. <i>Nat Neurosci</i> 24, 1302–1312. doi: 10.1038/s41593-
889	021-00886-6.
890	Yang, H., Liu, D., Zhao, C., Feng, B., Lu, W., Yang, X., et al. (2021b). Mendelian randomization
891	integrating GWAS and eQTL data revealed genes pleiotropically associated with major
892	depressive disorder. <i>Translational Psychiatry</i> 11, 225. doi: 10.1038/s41398-021-01348-0.
893	Yuan, Z., Zhu, H., Zeng, P., Yang, S., Sun, S., Yang, C., et al. (2020). Testing and controlling for
894	horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide
895	association studies. <i>Nat Commun</i> 11, 3861. doi: 10.1038/s41467-020-17668-6.
896	Zhang, J., Dutta, D., Köttgen, A., Tin, A., Schlosser, P., Grams, M. E., et al. (2021). Large Bi-
897	Ethnic Study of Plasma Proteome Leads to Comprehensive Mapping of cis-pQTL and
898	Models for Proteome-wide Association Studies. doi: 10.1101/2021.03.15.435533.
899	Zhang, S., Zhang, H., Zhou, Y., Qiao, M., Zhao, S., Kozlova, A., et al. (2020). Allele-specific
900	open chromatin in human iPSC neurons elucidates functional disease variants. <i>Science</i>
901	369, 561–565. doi: 10.1126/science.aay3983.
902	Zhou, D., Jiang, Y., Zhong, X., Cox, N. J., Liu, C., and Gamazon, E. R. (2020). A unified
903	framework for joint-tissue transcriptome-wide association and Mendelian randomization
904	analysis. <i>Nat Genet</i> 52, 1239–1246. doi: 10.1038/s41588-020-0706-2.
905	Zhu, Z., Zhang, F., Hu, H., Bakshi, A., Robinson, M. R., Powell, J. E., et al. (2016). Integration
906	of summary data from GWAS and eQTL studies predicts complex trait gene targets. <i>Nat</i>
907	<i>Genet</i> 48, 481–487. doi: 10.1038/ng.3538.
908 909 910 911 912	
913	